Dr. David Joseph Kwiatkowski, MD

Dr. Kwiatkowski practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Kwiatkowski's NPI, 1114010311, was assigned on October 2, 2006. Dr. Kwiatkowski graduated from Columbia University College of Physicians and Surgeons in 1979. Dr. Kwiatkowski holds Massachusetts license 54854MASS.

Dr. Kwiatkowski's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Kwiatkowski's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Kwiatkowski is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Kwiatkowski to 1 more hospital, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kwiatkowski practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Kwiatkowski's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Kwiatkowski is licensed in Massachusetts.

CMS data shows 428 Medicare services from Dr. Kwiatkowski across 5 procedure codes in 2024, for 127 Medicare patients. Medicare paid $34,474 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 127 Medicare patients who saw Dr. Kwiatkowski in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kwiatkowski's median patient age at 73, with 48% women.

In 2024, Dr. Kwiatkowski wrote 172 Medicare Part D claims for 49 patients. 80% of them were for generic drugs. CMS names the drug for 80 of them, across 4 drugs with 11 or more claims each, at $7,599 in total drug cost. In 2023, CMS named 56 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Kwiatkowski for performance year 2024, reported as part of a group. Dr. Kwiatkowski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kwiatkowski as offering telehealth.

Dmand AI links 197 papers to Dr. Kwiatkowski, published from 2010 to 2025. 2017 was the busiest year, with 16. The most frequent topics are Tuberous Sclerosis, Tuberous Sclerosis Complex 2 Protein and Tumor Suppressor Proteins. Dr. Kwiatkowski has published most often in Nat Commun. Dr. Kwiatkowski's most frequent co-authors are Elizabeth P. Henske, MD, Toni K. Choueiri, MD and Bruce Evan Johnson, MD.

Dmand AI links Dr. Kwiatkowski to 6 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Mesothelioma, Malignant, Pleural Neoplasms and Carcinoma, Transitional Cell. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Kwiatkowski that name 1 trial.

CMS Open Payments shows 31 general payments to Dr. Kwiatkowski from 5 drug and device companies from 2016 to 2023. Travel and lodging make up the largest share, 44% of the total. AstraZeneca Pharmaceuticals LP paid the most, $8,182. It also lists 9 research payments totaling $15,354 from 2020 to 2024, naming 1 clinical trial.

Dr. Kwiatkowski graduated from Columbia University College of Physicians and Surgeons in 1979.